[6-K] Vox Royalty Corp. Current Report (Foreign Issuer)
Kronos Bio, Inc. (KRON) filed a Form 15-12G with the U.S. SEC on 30 June 2025, certifying the termination of registration of its common stock under Section 12(g) of the Securities Exchange Act of 1934 and suspending the company鈥檚 duty to file reports under Sections 13 and 15(d).
The company relied on Rule 12g-4(a)(1) and Rule 12h-3(b)(1)(i), disclosing an approximate holder count of one. No other securities remain subject to reporting obligations. The notice was signed by Chief Financial Officer Michael Hearne.
Once the Form 15 becomes effective, Kronos Bio will no longer submit periodic filings such as Forms 10-K, 10-Q or 8-K, significantly reducing public disclosure and potentially affecting liquidity for remaining shareholders.
Kronos Bio, Inc. (KRON) ha presentato un modulo Form 15-12G alla SEC degli Stati Uniti il 30 giugno 2025, certificando la cessazione della registrazione delle sue azioni ordinarie ai sensi della Sezione 12(g) del Securities Exchange Act del 1934 e sospendendo l'obbligo della societ脿 di presentare rapporti ai sensi delle Sezioni 13 e 15(d).
La societ脿 si 猫 avvalsa della Regola 12g-4(a)(1) e della Regola 12h-3(b)(1)(i), dichiarando un numero approssimativo di azionisti pari a uno. Nessun altro titolo rimane soggetto agli obblighi di segnalazione. L'avviso 猫 stato firmato dal Chief Financial Officer, Michael Hearne.
Una volta che il Form 15 diventer脿 efficace, Kronos Bio non presenter脿 pi霉 documenti periodici come i moduli 10-K, 10-Q o 8-K, riducendo significativamente la trasparenza pubblica e potenzialmente influenzando la liquidit脿 per gli azionisti rimanenti.
Kronos Bio, Inc. (KRON) present贸 un Formulario 15-12G ante la SEC de EE.UU. el 30 de junio de 2025, certificando la terminaci贸n del registro de sus acciones ordinarias bajo la Secci贸n 12(g) de la Ley de Intercambio de Valores de 1934 y suspendiendo la obligaci贸n de la compa帽铆a de presentar informes bajo las Secciones 13 y 15(d).
La compa帽铆a se bas贸 en la Regla 12g-4(a)(1) y la Regla 12h-3(b)(1)(i), revelando un conteo aproximado de accionistas de uno. No quedan otros valores sujetos a obligaciones de reporte. El aviso fue firmado por el Director Financiero, Michael Hearne.
Una vez que el Formulario 15 entre en vigor, Kronos Bio dejar谩 de presentar informes peri贸dicos como los Formularios 10-K, 10-Q o 8-K, reduciendo significativamente la divulgaci贸n p煤blica y afectando potencialmente la liquidez para los accionistas restantes.
Kronos Bio, Inc. (KRON)鞚� 2025雲� 6鞗� 30鞚� 氙戈淡 SEC鞐� Form 15-12G毳� 鞝滌稖頃橃棳 1934雲� 歃濌秾瓯半灅氩� 靹轨厴 12(g)鞐� 霐半ジ 氤错喌欤� 霌彪 膦呺毳� 鞚胳頃橁碃 靹轨厴 13 氚� 15(d)鞐� 霐半ジ 氤搓碃 鞚橂毳� 欷戨嫧頃橃榾鞀惦媹雼�.
须岇偓电� 攴滌箼 12g-4(a)(1) 氚� 攴滌箼 12h-3(b)(1)(i)毳� 攴缄卑搿� 鞎� 欤检＜ 靾橂ゼ 1氇呾溂搿� 氤搓碃頃橃榾鞀惦媹雼�. 氤搓碃 鞚橂臧� 雮晞 鞛堧姅 雼るジ 歃濌秾鞚� 鞐嗢姷雼堧嫟. 頃措嫻 韱奠電� 斓滉碃鞛毂呾瀯鞛�(CFO) Michael Hearne臧� 靹滊獏頃橃榾鞀惦媹雼�.
Form 15臧� 須牓鞚� 氚滍湗頃橂┐ Kronos Bio電� 雿� 鞚挫儊 10-K, 10-Q, 8-K 鞏戩嫕瓿� 臧欖潃 鞝曣赴 氤搓碃靹滊ゼ 鞝滌稖頃橃 鞎婌晞 瓿店皽 鞝曤炒臧� 韥矊 欷勳柎霌り碃 雮潃 欤检＜霌れ潣 鞙犽彊靹膘棎 鞓來枼鞚� 氙胳範 靾� 鞛堨姷雼堧嫟.
Kronos Bio, Inc. (KRON) a d茅pos茅 un formulaire 15-12G aupr猫s de la SEC am茅ricaine le 30 juin 2025, certifiant la cessation de l鈥檈nregistrement de ses actions ordinaires conform茅ment 脿 la Section 12(g) du Securities Exchange Act de 1934 et suspendant l鈥檕bligation de la soci茅t茅 de d茅poser des rapports en vertu des Sections 13 et 15(d).
La soci茅t茅 s鈥檈st appuy茅e sur la R猫gle 12g-4(a)(1) et la R猫gle 12h-3(b)(1)(i), divulguant un nombre approximatif d鈥檜n d茅tenteur. Aucun autre titre ne reste soumis aux obligations de d茅claration. L鈥檃vis a 茅t茅 sign茅 par le Directeur Financier, Michael Hearne.
Une fois que le formulaire 15 sera effectif, Kronos Bio ne soumettra plus de d茅p么ts p茅riodiques tels que les formulaires 10-K, 10-Q ou 8-K, r茅duisant ainsi consid茅rablement la divulgation publique et pouvant affecter la liquidit茅 des actionnaires restants.
Kronos Bio, Inc. (KRON) reichte am 30. Juni 2025 ein Formular 15-12G bei der US-SEC ein und best盲tigte damit die Beendigung der Registrierung seiner Stammaktien gem盲脽 Abschnitt 12(g) des Securities Exchange Act von 1934 sowie die Aussetzung der Berichtspflicht nach den Abschnitten 13 und 15(d).
Das Unternehmen st眉tzte sich auf Regel 12g-4(a)(1) und Regel 12h-3(b)(1)(i) und gab eine ungef盲hre Aktion盲rszahl von einem an. Es verbleiben keine weiteren Wertpapiere, die berichtspflichtig sind. Die Mitteilung wurde vom Chief Financial Officer, Michael Hearne, unterzeichnet.
Sobald das Formular 15 wirksam wird, wird Kronos Bio keine periodischen Einreichungen wie Formulare 10-K, 10-Q oder 8-K mehr vorlegen, was die 枚ffentliche Offenlegung erheblich reduziert und m枚glicherweise die Liquidit盲t der verbleibenden Aktion盲re beeintr盲chtigt.
- None.
- Termination of SEC registration eliminates mandatory public disclosures, reducing transparency and likely decreasing trading liquidity for remaining shareholders.
Insights
TL;DR: Deregistration ends SEC reporting, sharply reducing transparency and likely hurting public shareholders.
Filing Form 15 under Rules 12g-4(a)(1) and 12h-3(b)(1)(i) is a decisive step to exit the public-company reporting framework. With only one holder of record, KRON meets the statutory thresholds, so the termination should take effect automatically. While legally permissible, the move eliminates audited financial statements, proxy disclosures and current reports, removing critical oversight mechanisms. For investors still holding shares, reduced information flow may lower market liquidity and widen bid-ask spreads. The action is therefore material and, from a governance standpoint, negative for minority shareholders.
TL;DR: Form 15 filing is materially negative; future financial data will disappear, complicating valuation.
This filing signals an immediate shift from public to private-style disclosure. Without periodic SEC reports, fundamental analysis becomes difficult, forcing investors to rely on limited or voluntary information. Liquidity constraints typically follow, as many institutional mandates restrict holdings in non-reporting securities. Consequently, the risk-adjusted required return on KRON stock rises, pressuring valuation. Unless an exit event鈥攕uch as a tender offer鈥攆ollows, shareholders face higher uncertainty.
Kronos Bio, Inc. (KRON) ha presentato un modulo Form 15-12G alla SEC degli Stati Uniti il 30 giugno 2025, certificando la cessazione della registrazione delle sue azioni ordinarie ai sensi della Sezione 12(g) del Securities Exchange Act del 1934 e sospendendo l'obbligo della societ脿 di presentare rapporti ai sensi delle Sezioni 13 e 15(d).
La societ脿 si 猫 avvalsa della Regola 12g-4(a)(1) e della Regola 12h-3(b)(1)(i), dichiarando un numero approssimativo di azionisti pari a uno. Nessun altro titolo rimane soggetto agli obblighi di segnalazione. L'avviso 猫 stato firmato dal Chief Financial Officer, Michael Hearne.
Una volta che il Form 15 diventer脿 efficace, Kronos Bio non presenter脿 pi霉 documenti periodici come i moduli 10-K, 10-Q o 8-K, riducendo significativamente la trasparenza pubblica e potenzialmente influenzando la liquidit脿 per gli azionisti rimanenti.
Kronos Bio, Inc. (KRON) present贸 un Formulario 15-12G ante la SEC de EE.UU. el 30 de junio de 2025, certificando la terminaci贸n del registro de sus acciones ordinarias bajo la Secci贸n 12(g) de la Ley de Intercambio de Valores de 1934 y suspendiendo la obligaci贸n de la compa帽铆a de presentar informes bajo las Secciones 13 y 15(d).
La compa帽铆a se bas贸 en la Regla 12g-4(a)(1) y la Regla 12h-3(b)(1)(i), revelando un conteo aproximado de accionistas de uno. No quedan otros valores sujetos a obligaciones de reporte. El aviso fue firmado por el Director Financiero, Michael Hearne.
Una vez que el Formulario 15 entre en vigor, Kronos Bio dejar谩 de presentar informes peri贸dicos como los Formularios 10-K, 10-Q o 8-K, reduciendo significativamente la divulgaci贸n p煤blica y afectando potencialmente la liquidez para los accionistas restantes.
Kronos Bio, Inc. (KRON)鞚� 2025雲� 6鞗� 30鞚� 氙戈淡 SEC鞐� Form 15-12G毳� 鞝滌稖頃橃棳 1934雲� 歃濌秾瓯半灅氩� 靹轨厴 12(g)鞐� 霐半ジ 氤错喌欤� 霌彪 膦呺毳� 鞚胳頃橁碃 靹轨厴 13 氚� 15(d)鞐� 霐半ジ 氤搓碃 鞚橂毳� 欷戨嫧頃橃榾鞀惦媹雼�.
须岇偓电� 攴滌箼 12g-4(a)(1) 氚� 攴滌箼 12h-3(b)(1)(i)毳� 攴缄卑搿� 鞎� 欤检＜ 靾橂ゼ 1氇呾溂搿� 氤搓碃頃橃榾鞀惦媹雼�. 氤搓碃 鞚橂臧� 雮晞 鞛堧姅 雼るジ 歃濌秾鞚� 鞐嗢姷雼堧嫟. 頃措嫻 韱奠電� 斓滉碃鞛毂呾瀯鞛�(CFO) Michael Hearne臧� 靹滊獏頃橃榾鞀惦媹雼�.
Form 15臧� 須牓鞚� 氚滍湗頃橂┐ Kronos Bio電� 雿� 鞚挫儊 10-K, 10-Q, 8-K 鞏戩嫕瓿� 臧欖潃 鞝曣赴 氤搓碃靹滊ゼ 鞝滌稖頃橃 鞎婌晞 瓿店皽 鞝曤炒臧� 韥矊 欷勳柎霌り碃 雮潃 欤检＜霌れ潣 鞙犽彊靹膘棎 鞓來枼鞚� 氙胳範 靾� 鞛堨姷雼堧嫟.
Kronos Bio, Inc. (KRON) a d茅pos茅 un formulaire 15-12G aupr猫s de la SEC am茅ricaine le 30 juin 2025, certifiant la cessation de l鈥檈nregistrement de ses actions ordinaires conform茅ment 脿 la Section 12(g) du Securities Exchange Act de 1934 et suspendant l鈥檕bligation de la soci茅t茅 de d茅poser des rapports en vertu des Sections 13 et 15(d).
La soci茅t茅 s鈥檈st appuy茅e sur la R猫gle 12g-4(a)(1) et la R猫gle 12h-3(b)(1)(i), divulguant un nombre approximatif d鈥檜n d茅tenteur. Aucun autre titre ne reste soumis aux obligations de d茅claration. L鈥檃vis a 茅t茅 sign茅 par le Directeur Financier, Michael Hearne.
Une fois que le formulaire 15 sera effectif, Kronos Bio ne soumettra plus de d茅p么ts p茅riodiques tels que les formulaires 10-K, 10-Q ou 8-K, r茅duisant ainsi consid茅rablement la divulgation publique et pouvant affecter la liquidit茅 des actionnaires restants.
Kronos Bio, Inc. (KRON) reichte am 30. Juni 2025 ein Formular 15-12G bei der US-SEC ein und best盲tigte damit die Beendigung der Registrierung seiner Stammaktien gem盲脽 Abschnitt 12(g) des Securities Exchange Act von 1934 sowie die Aussetzung der Berichtspflicht nach den Abschnitten 13 und 15(d).
Das Unternehmen st眉tzte sich auf Regel 12g-4(a)(1) und Regel 12h-3(b)(1)(i) und gab eine ungef盲hre Aktion盲rszahl von einem an. Es verbleiben keine weiteren Wertpapiere, die berichtspflichtig sind. Die Mitteilung wurde vom Chief Financial Officer, Michael Hearne, unterzeichnet.
Sobald das Formular 15 wirksam wird, wird Kronos Bio keine periodischen Einreichungen wie Formulare 10-K, 10-Q oder 8-K mehr vorlegen, was die 枚ffentliche Offenlegung erheblich reduziert und m枚glicherweise die Liquidit盲t der verbleibenden Aktion盲re beeintr盲chtigt.
FAQ
What did Kronos Bio (KRON) file with the SEC on June 30, 2025?
Which rules did Kronos Bio rely on for deregistration?
How many holders of record does Kronos Bio report in the filing?
What class of securities is covered by Kronos Bio's Form 15?
Who signed the Form 15 on behalf of Kronos Bio?
Does Kronos Bio have any other securities that remain registered?
